Effects on coagulation and fibrinolysis with reduced versus full systemic heparinization and heparin-coated cardiopulmonary bypass. 1995

E Ovrum, and F Brosstad, and E Am Holen, and G Tangen, and M Abdelnoor
Oslo Heart Center, Department of Cardiac Surgery and Anesthesiology, Norway.

BACKGROUND Extracorporeal circulation with circuits coated with surface-bound heparin has allowed reduced levels of systemic heparinization. Clinical benefits have included reduced postoperative bleeding and less homologous blood usage. However, the effects on the hemostatic and fibrinolytic systems have remained in part unknown. RESULTS Indications of thrombin generation, platelet activation, and fibrinolytic activity were investigated in patients undergoing coronary artery bypass surgery. Two groups were perfused with cardiopulmonary bypass (CPB) circuits completely coated with surface-bound heparin: one group with low systemic heparin dose (activated clotting time [ACT] > 250 seconds; n = 17) and a second group having a full heparin dose (ACT > 480 seconds; n = 18). A third control group was perfused with ordinary uncoated circuits and full heparin dose (n = 17). The plasma level of thrombin-antithrombin complex and prothrombin fragment 1.2 increased in all groups during bypass, and somewhat more in both the heparin-coated groups toward the end of CPB, compared with the control group (P < .01). However, the increase during CPB was minimal compared with the major elevation observed 2 hours after surgery in all groups. Platelet release of beta-thromboglobulin increased in all groups (P < .01) during CPB and significantly more in the high-dose group compared with the other two groups (P = .03). Fibrinolytic activities were similar in all groups, and there were no indications of major consumption of coagulation factors. CONCLUSIONS Reduced systemic heparinization (ACT > 250 seconds) in patients having extracorporeal circulation with completely heparin-coated circuits did not lead to increased thrombogenicity. Thrombin formation remained within low ranges during CPB compared with patients receiving a full heparin dose and with the major elevations observed after surgery.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001777 Blood Coagulation The process of the interaction of BLOOD COAGULATION FACTORS that results in an insoluble FIBRIN clot. Blood Clotting,Coagulation, Blood,Blood Clottings,Clotting, Blood
D002315 Cardiopulmonary Bypass Diversion of the flow of blood from the entrance of the right atrium directly to the aorta (or femoral artery) via an oxygenator thus bypassing both the heart and lungs. Heart-Lung Bypass,Bypass, Cardiopulmonary,Bypass, Heart-Lung,Bypasses, Cardiopulmonary,Bypasses, Heart-Lung,Cardiopulmonary Bypasses,Heart Lung Bypass,Heart-Lung Bypasses
D005260 Female Females
D005342 Fibrinolysis The natural enzymatic dissolution of FIBRIN. Fibrinolyses
D006493 Heparin A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts. Heparinic Acid,alpha-Heparin,Heparin Sodium,Liquaemin,Sodium Heparin,Unfractionated Heparin,Heparin, Sodium,Heparin, Unfractionated,alpha Heparin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

E Ovrum, and F Brosstad, and E Am Holen, and G Tangen, and M Abdelnoor
October 1999, The Annals of thoracic surgery,
E Ovrum, and F Brosstad, and E Am Holen, and G Tangen, and M Abdelnoor
February 1997, The Annals of thoracic surgery,
E Ovrum, and F Brosstad, and E Am Holen, and G Tangen, and M Abdelnoor
October 1991, The Thoracic and cardiovascular surgeon,
E Ovrum, and F Brosstad, and E Am Holen, and G Tangen, and M Abdelnoor
January 1996, ASAIO journal (American Society for Artificial Internal Organs : 1992),
E Ovrum, and F Brosstad, and E Am Holen, and G Tangen, and M Abdelnoor
September 1989, The Journal of thoracic and cardiovascular surgery,
E Ovrum, and F Brosstad, and E Am Holen, and G Tangen, and M Abdelnoor
May 1994, Acta anaesthesiologica Scandinavica,
E Ovrum, and F Brosstad, and E Am Holen, and G Tangen, and M Abdelnoor
August 1994, The Annals of thoracic surgery,
E Ovrum, and F Brosstad, and E Am Holen, and G Tangen, and M Abdelnoor
September 1999, The journal of extra-corporeal technology,
E Ovrum, and F Brosstad, and E Am Holen, and G Tangen, and M Abdelnoor
March 2000, The Annals of thoracic surgery,
E Ovrum, and F Brosstad, and E Am Holen, and G Tangen, and M Abdelnoor
June 2002, Journal of cardiothoracic and vascular anesthesia,
Copied contents to your clipboard!